Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2206)	2/20/2008 3:16:02 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

INGN has been up 12.8% & still is up 9.85% on volume of 199.4Ks, which is above its ADV, but the stock is still below the resistance at the $3 level.<g> bigcharts.marketwatch.com The short ratio is still > 30x its ADV & it seems that the shorts are starting to get nervous about any possible positive news on Advexin's NDAs.<g> With some good news the stock can easily double to the $6 level.<g> bigcharts.marketwatch.com Last week it announced that its INGN 225 was starting a PII in patients with SCLC that was supported by $1.3M award from NCI The PII will be led by Dr. Alberto Chiappori, in the Department of Interdisciplinary Oncology at Moffitt, & will evaluate the efficacy and safety of INGN 225 in as many as 80 patients with extensive stage SCLC at multiple centers. Bernard